Praxis Precision Upbeat on CCRX and Relutrigine approvals

Praxis announced positive mid-cycle FDA meetings and BIMO inspections for ulixacaltamide and relutrigine. These pivotal CNS drug programs, with potential PDUFA dates in late 2026/2027, are advancing commercial infrastructure as the biotech maintains a $1.4 billion cash runway into 2028.